NT5E and non-small cell lung carcinoma: Further, targeting CD73 has also recently been shown to be a promising therapeutic strategy, wherein Phase II clinical trials combining anti-CD73 with anti-PD-L1 elicit increased response rate and progression-free survival compared to anti-PD-L1 monotherapy in patients with non-small cell lung cancer[93].